Browse Conditions Browse Medicines

NICE guidance: Prostate cancer: diagnosis and management

For Prostate cancer

The National Institute for Health and Care Excellence (NICE) have published updated guidelines on the diagnosis and management of prostate cancer.

This guideline covers diagnosing and managing prostate cancer in secondary care. It offers information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It includes recommendations on follow-up in primary care for people with a diagnosis of prostate cancer.

The guideline is intended for use by:
  • People with prostate cancer, their families and carers
  • Healthcare professionals.
  • Commissioners and providers of prostate cancer services

Prostate cancer: the care you should expect
Prostate cancer is the second most common cancer in the UK. Prostate cancer often grows very slowly at first without even causing symptoms. Treatment may not be needed straightaway, but this depends on whether or not the cancer has spread within the prostate or to other parts of the body. This means decisions about treatment, what it should be and when it should start, are different for everyone.

We want this guideline to make a difference to people with prostate cancer by making sure:
  • your doctor explains the different tests used to diagnose prostate cancer, what they involve and how the results are used
  • your care team puts you at the centre of decisions about tests and treatments and helps you understand the possible benefits and risks
  • you have time and support to weigh up your choices – for example, between starting treatment or a period of regular monitoring.

© NICE [2019]

Prostate cancer: diagnosis and management. NICE guideline [NG131] Published date: May 2019
Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

The information provided by NICE was accurate at the time this article was issued.

NICE guidance: Prostate cancer: diagnosis and management

Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.

About condition